 FSD Pharma is a unique cannabis company, and that the company not only grows its plants but it also is working with synthetic cannabinoids. Joining me now is CEO, Dr. Raza Bakhari. This is unique because so many companies when they work with the cannabis plant will often say that the synthetics don't have the same effectiveness as the natural plants. But your company is getting involved in both sides of this. So explain this to me because I'm very curious about that. Thank you, Namo Vandebra, for having me on your program. We clearly are, as our core business, is to grow medicinal grade cannabis. However, in modern-day FDA-approved processes, every drug is synthesized or biosynthesized in a lab. This is a myth that synthetic drugs or products are not effective. But generally speaking, the medicinal grade cannabis grow that we do is and the illnesses and disease conditions that the strains are treating are important, not just us but many other competitors that we have are actually filling a void in this expanding marketplace, which I believe by year 2025 is going to be a $150 billion market size across the world, outside the United States. We will uplist, we took the vote, and we will hopefully become the 10th company to be on a major US exchange. So we're very excited about that opportunity. Our company is domiciled in outside Toronto and Cobra, which is a field-good town. However, we are assembling our biosciences division and the team and the leadership from greater Philadelphia area. In a lot of the states that start out with legalization of medical marijuana, when they switch to having recreational adult use, we see that the patient licenses drop, that it seems like some of the business drops for the medical marijuana. How are you going to be able to address that if you're so focused on medical marijuana? I think that there is in every industry, there is certain level of cannibalization of illicit use and it comes with the territory. I don't think so. We must account for as seasoned business operators. We have to account for these kind of challenges that we face, but in the face of these challenges also are opportunities. This is in a recreational user is not really looking for a indoor hydroponic high yield grow product, which is rather expensive. They will always look for a cheaper and the most inexpensive alternative. So I think there is not the market that we really in any case are losing to begin with. However, these are an essential challenge of any of this industry as it will be in other industries. Great. Well, we will keep our eye out on FSB pharma. It sounds like you have a lot of news that's going to be coming out soon. That's Dr. Reza Balkari and I'm Deborah Fortart with the Green Market Report.